The company’s representatives called the specialists to note that the Pharmasyntez-Tyumen plant can currently produce the whole suite of oral antihyperglycemic drugs the practitioners need to be in compliance with the last requirements to standards for the treatment of type 2 diabetes mellitus. It is very important to note that various well regulated production lines of the plant make it possible to produce both tablet and infusion formulations.

Thus, Pharmasyntez-Tyumen contributes a lot to innovations in the Russian pharmaceutical industry by manufacturing the first original domestic dipeptidyl peptidase-4 inhibitor under the brand name SatRX® (Gosogliptin). This group drugs are highly demanded in actual clinical practice, since they can correct seven out of eleven possible defects in blood glucose growth. The Pharmasyntez Group is engaged in a full cycle production of SatRX®, starting from synthesis of the drug substance at the Bratsk plant till finished formulation manufactured at the Tyumen plant.

The main purpose of Pharmasyntez is to provide patients suffering from diabetes mellitus with an affordable and efficient treatment within import substitution. To achieve this, the Company implements the project “Construction project of a plant for hormonal drugs and radiopaque substances” at the premises of Pharmasyntez-Tyumen, which will contribute to resolving important challenges in pharmaceutical industry.